Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Researchers identify gene that could be key to future HIV vaccine
OHSU researchers identified a gene, UL18, that could hinder HIV vaccine effectiveness in humans, paving the way for improved vaccine development against HIV, cancer, and malaria. Human clinical trials of the HIV vaccine, without UL18, are underway by Vir Biotechnology, NIH, and the Bill and Melinda Gates Foundation.
What's Next: Vir Biotechnology's Earnings Preview
Vir Biotechnology (VIR) to announce Q3 2024 earnings on 2024-10-31, with analysts estimating an EPS of $-1.05. Investors anticipate potential positive guidance. Last quarter, EPS missed by $0.13, causing a 5.34% share price drop.
Red Biotechnology Market Growth Analysis, Trends, Share
The red biotechnology market is projected to grow from $509.71 billion in 2023 to $867.20 billion by 2028, driven by advancements in personalized medicine, biosimilars, and genetic engineering. Major players include Pfizer, Roche, Bayer, and Amgen.
Vir Biotechnology (VIR) Scheduled to Post Earnings on Thursday
Vir Biotechnology (NASDAQ:VIR) is set to release Q3 earnings on Oct 31, with analysts forecasting a loss of $0.96 per share. The company reported a loss of $1.02 per share in Q2, missing estimates by $0.13, with revenue of $3.08M, down 19% YoY. Insiders, including Director Janet Napolitano, have recently sold shares. Analysts maintain a 'Moderate Buy' consensus rating with a target price of $36.80.
nVerses Capital LLC Invests $56000 in Vir Biotechnology, Inc. (NASDAQ:VIR)
nVerses Capital LLC acquired a new stake in Vir Biotechnology, Inc. during Q3, while other hedge funds also adjusted their holdings. Analysts have given Vir Biotechnology an average rating of 'Moderate Buy' with a consensus target price of $36.80. The stock opened at $7.65 on Tuesday, with a 52-week range of $7.12 to $13.09. Vir Biotechnology reported a revenue of $3.08 million for the quarter, missing analysts' expectations. Director Janet Napolitano sold 12,190 shares in September. The company focuses on developing therapeutic products for serious infectious diseases.
Shares Sold by AQR Capital Management LLC
AQR Capital Management reduced its Vir Biotechnology holdings by 42.3% in Q2. Other investors also adjusted their stakes, with Point72 Asia Singapore and Point72 Hong Kong increasing theirs significantly. Analysts have a 'Moderate Buy' consensus rating for VIR, with an average target price of $36.80. Insider Janet Napolitano sold 12,190 shares in September. VIR's stock opened at $7.63 on Friday, with a market cap of $1.04 billion. The company reported a Q2 EPS of -$1.02, missing estimates, and revenue of $3.08 million, down 19% YoY.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial
Vir Biotechnology to provide Q3 2024 corporate update and financial results on Oct 31, 2024, hosting a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Details available on www.vir.bio and investors.vir.bio/events-presentations.
© Copyright 2024. All Rights Reserved by MedPath